![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, June 17, 2014 10:56:50 AM
"GW Pharmaceuticals PLC- ADR (NASDAQ:GWP*) reports preliminary data on 27 children and young adults with treatment-resistant epilepsy who have been treated with its investigational cannabidiol product candidate Epidiolex for a period of 12 weeks. Of the 27 patients, nine have Dravet syndrome and the remaining 18 have treatment-resistant epilepsies with convulsive and/or non-convulsive siezures.The mean overall reduction in seizure frequency compared to baseline was 44%."
I bought this stock a year or so ago at $8 and sold it at $11. What a dope.
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM